Searching for treatments for non-G12C-KRAS mutant cancers.

ABSTRACT: KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS^G12C mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF-MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers.

SUBMITTER: Guo C 

PROVIDER: S-EPMC8405631 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature